ivosidenib + azacitidine

**Ivosidenib + azacitidine** is a fixed combination therapy consisting of ivosidenib, a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, and azacitidine, a DNA hypomethylating agent. This combination is FDA-approved for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation in adults aged 75 years or older, or adults with comorbidities that preclude intensive induction chemotherapy. Ivosidenib targets and inhibits mutant IDH1, reducing abnormal metabolite formation and allowing normal cell differentiation. Azacitidine incorporates into DNA and RNA, causing hypomethylation, apoptosis, and cell death of abnormal hematopoietic cells. The combination significantly improves overall survival, event-free survival, and the rate and duration of complete remission compared to azacitidine alone. Major adverse effects include differentiation syndrome, QT interval prolongation, gastrointestinal and constitutional symptoms, and cytopenias[1][2][3][5].

Brand names

Tibsovo + azacitidine

Other names

ivosidenib plus azacitidine